Acquisition enhances Aegis’s toxicology portfolio, while HealthTrackRx expands its PCR infectious disease testing
Aegis Sciences Corporation, a health care testing laboratory based in Nashville, Tenn., today announced its acquisition of the HealthTrackRx Toxicology line of business.
Aegis has provided science-driven drug testing and consulting services since 1990. The laboratory delivers evidence-based, clinically actionable information related to medication compliance, substance abuse, and drug-drug interactions through definitive testing of urine, oral fluid, or blood specimens.
“Clinicians need the diagnostic ability to detect the most relevant prescribed, illicit, and synthetic drugs that directly affect patient outcomes,” said Dr. Frank Basile, Aegis Sciences Corporation CEO. “This acquisition provides the opportunity for Aegis to deliver the most comprehensive clinical toxicology testing available to more providers.”
HealthTrackRx, the nation’s premier polymerase chain reaction (RT-PCR)-based infectious disease laboratory, was founded with a focus on clinical toxicology testing. Recently, the company has transitioned its growth strategy to infectious disease testing and combating antimicrobial resistance.
“As we aggressively expand our infection detection capabilities and deliver next-morning PCR results nationwide, toxicology has become a declining portion of our clinical testing portfolio,” said Martin Price, HealthTrackRx CEO and chairman. “We are grateful for the opportunity to serve our toxicology clients over the past decade and know they are in good hands with Aegis,” Price continued.
“Aegis’s health care testing services are designed uniquely for the specialties we serve. We look forward to helping more clinicians make better decisions for their patients through our innovative approach,” said Mike Ziegler, chief commercial officer.
Source: Company Press Release